The proteasome inhibitor bortezomib has been shown to sensitise cells to TRAIL in other types of cancer.29 We therefore aimed to investigate whether concentrations of bortezomib with only low single-agent toxicity synergise with TRAIL in HPV+ HNSCC cells. This evidence concerns the gene TNFSF10 and head and neck squamous cell carcinoma.